Inhibikase Therapeutics, Inc. SEC filings IKT
Inhibikase Therapeutics, Inc. has 368 filings in SEC EDGAR's recent list, going back to Aug 31, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Auditor change
|
Aug 26, 2026 | Aug 21, 2026 |
| S-8 | Employee stock plan registration | Aug 11, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 29, 2026 | Jun 26, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 26, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 7, 2026 | Apr 7, 2026 |
| S-8 | Employee stock plan registration | Mar 26, 2026 | — |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Other events
|
Dec 19, 2025 | Dec 19, 2025 |
| 424B5 | Prospectus supplement | Dec 19, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Nov 21, 2025 | Nov 20, 2025 |
| 424B5 | Prospectus supplement | Nov 21, 2025 | — |
| 424B5 | Prospectus supplement | Nov 20, 2025 | — |
| 8-K |
Current report
Other events
|
Nov 20, 2025 | Nov 20, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2025 | Aug 14, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2025 | Jun 27, 2025 |
| EFFECT | Filing | Jun 27, 2025 | — |
| CORRESP | Letter to the SEC | Jun 25, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2025 | — |
| S-3 | Shelf registration | Jun 20, 2025 | — |
| DEFA14A | Additional proxy material | Jun 12, 2025 | — |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| ARS | Annual report to shareholders | May 12, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| DEF 14A | Proxy statement | May 12, 2025 | Jun 27, 2025 |
| PRE 14A | Preliminary proxy statement | May 2, 2025 | Jun 27, 2025 |
| 10-K/A | Amended annual report | Apr 25, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 14, 2025 | Apr 11, 2025 |
| S-8 | Employee stock plan registration | Mar 27, 2025 | — |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Feb 24, 2025 | Feb 21, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 18, 2025 | Feb 13, 2025 |
| S-8 | Employee stock plan registration | Feb 4, 2025 | — |
| 8-K |
Current report
Other events
|
Jan 29, 2025 | Jan 29, 2025 |
| EFFECT | Filing | Jan 16, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2025 | — |
| S-3 | Shelf registration | Jan 10, 2025 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jan 6, 2025 | Jan 3, 2025 |
| EFFECT | Filing | Dec 5, 2024 | — |
| 8-K |
Current report
Agreement ended
|
Dec 5, 2024 | Dec 2, 2024 |
| 424B3 | Prospectus | Dec 5, 2024 | — |
| CORRESP | Letter to the SEC | Dec 3, 2024 | — |
| S-3/A | Filing | Dec 3, 2024 | — |
| S-3 | Shelf registration | Nov 18, 2024 | — |
| DEF 14A | Proxy statement | Nov 18, 2024 | Jan 3, 2025 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| PRE 14A | Preliminary proxy statement | Nov 8, 2024 | Jan 3, 2025 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Oct 22, 2024 | Oct 21, 2024 |
| SC 14F1 | Filing | Oct 11, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure, Other events
|
Oct 10, 2024 | Oct 9, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2024 | Oct 9, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Aug 6, 2024 | Aug 5, 2024 |
| 424B3 | Prospectus | Jun 27, 2024 | — |
| EFFECT | Filing | Jun 26, 2024 | — |
| CORRESP | Letter to the SEC | Jun 24, 2024 | — |
| DEFA14A | Additional proxy material | Jun 21, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2024 | — |
| DEF 14A | Proxy statement | Jun 20, 2024 | Aug 5, 2024 |
| S-1 | Registration statement | Jun 18, 2024 | — |
| PRE 14A | Preliminary proxy statement | Jun 10, 2024 | Aug 5, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2024 | Jun 7, 2024 |
| D | Filing | Jun 4, 2024 | — |
| 424B5 | Prospectus supplement | May 22, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 20, 2024 | May 20, 2024 |
| 424B5 | Prospectus supplement | May 20, 2024 | — |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| RW | Filing | May 15, 2024 | — |
| S-1/A | Amended registration statement | May 9, 2024 | — |
| S-1/A | Amended registration statement | May 9, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 30, 2024 | Apr 26, 2024 |
| S-1/A | Amended registration statement | Apr 29, 2024 | — |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| S-1/A | Amended registration statement | Apr 25, 2024 | — |
| S-1 | Registration statement | Apr 19, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 19, 2024 | Apr 18, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2024 | Jun 7, 2024 |
| 8-K/A |
Amended current report
Officer or director change
|
Apr 2, 2024 | Jan 16, 2024 |
| 10-K | Annual report | Mar 27, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Other events
|
Feb 7, 2024 | Feb 7, 2024 |
| 424B5 | Prospectus supplement | Feb 1, 2024 | — |
| 8-K |
Current report
Material agreement
|
Feb 1, 2024 | Feb 1, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 16, 2024 | Jan 16, 2024 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 10-K/A | Amended annual report | Oct 16, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 20, 2023 | Sep 20, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Other events
|
Jul 17, 2023 | Jul 17, 2023 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Jun 29, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 28, 2023 | Jun 23, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | May 12, 2023 | — |
| ARS | Annual report to shareholders | May 5, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | May 5, 2023 | Jun 23, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2023 | Jun 23, 2023 |
| EFFECT | Filing | Apr 4, 2023 | — |
| 424B3 | Prospectus | Apr 4, 2023 | — |
| POS AM | Filing | Mar 31, 2023 | — |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 22, 2023 | Mar 22, 2023 |
| 8-K |
Current report
Other events
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 6, 2023 | Mar 1, 2023 |
| 424B3 | Prospectus | Feb 8, 2023 | — |
| EFFECT | Filing | Feb 7, 2023 | — |
| D | Filing | Feb 7, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2023 | — |
| CORRESP | Letter to the SEC | Feb 3, 2023 | — |
| S-1 | Registration statement | Feb 2, 2023 | — |
| 424B5 | Prospectus supplement | Jan 27, 2023 | — |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Regulation FD disclosure
|
Jan 26, 2023 | Jan 25, 2023 |
| 8-K |
Current report
Other events
|
Jan 25, 2023 | Jan 25, 2023 |
| 8-K |
Current report
Listing notice
|
Jan 24, 2023 | Jan 24, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 17, 2022 | Nov 14, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Other events
|
Nov 7, 2022 | Nov 7, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2022 | Sep 16, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 1, 2022 | Sep 1, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 15, 2022 | Aug 15, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Listing notice
|
Jul 29, 2022 | Jul 25, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2022 | Jun 24, 2022 |
| DEFR14A | Filing | Jun 22, 2022 | — |
| 8-K |
Current report
Material agreement
|
May 17, 2022 | May 16, 2022 |
| 424B5 | Prospectus supplement | May 17, 2022 | — |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | May 3, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 24, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2022 | Jun 24, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 21, 2022 | Apr 21, 2022 |
| 10-K | Annual report | Mar 31, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 24, 2022 | Mar 18, 2022 |
| 8-K/A |
Amended current report
Officer or director change
|
Mar 21, 2022 | Mar 3, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 8, 2022 | Mar 3, 2022 |
| EFFECT | Filing | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 9, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2022 | — |
| S-3 | Shelf registration | Feb 7, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 20, 2022 | Jan 20, 2022 |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2021 | Oct 19, 2021 |
| S-8 | Employee stock plan registration | Sep 15, 2021 | — |
| 8-K |
Current report
Other events
|
Sep 8, 2021 | Sep 1, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 17, 2021 | Aug 17, 2021 |
| 10-Q | Quarterly report | Aug 16, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2021 | Jun 25, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 21, 2021 | Jun 18, 2021 |
| 424B4 | Prospectus | Jun 17, 2021 | — |
| 8-K |
Current report
Material agreement
|
Jun 16, 2021 | Jun 15, 2021 |
| EFFECT | Filing | Jun 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| S-1 | Registration statement | Jun 11, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| DRS | Filing | Jun 2, 2021 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 1, 2021 | Jun 1, 2021 |
| 10-Q | Quarterly report | May 17, 2021 | Mar 31, 2021 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 25, 2021 |
| 8-K |
Current report
Results of operations
|
Apr 1, 2021 | Apr 1, 2021 |
| 10-K | Annual report | Mar 31, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 8, 2021 | Feb 7, 2021 |
| 8-K |
Current report
Unregistered share sale, Bylaw or fiscal year change, Other events
|
Dec 29, 2020 | Dec 22, 2020 |
| 424B4 | Prospectus | Dec 28, 2020 | — |
| EFFECT | Filing | Dec 22, 2020 | — |
| S-1MEF | Filing | Dec 22, 2020 | — |
| CORRESP | Letter to the SEC | Dec 17, 2020 | — |
| CORRESP | Letter to the SEC | Dec 17, 2020 | — |
| S-1/A | Amended registration statement | Dec 4, 2020 | — |
| CORRESP | Letter to the SEC | Nov 12, 2020 | — |
| CORRESP | Letter to the SEC | Nov 12, 2020 | — |
| CORRESP | Letter to the SEC | Nov 6, 2020 | — |
| CORRESP | Letter to the SEC | Nov 6, 2020 | — |
| S-1/A | Amended registration statement | Nov 3, 2020 | — |
| CORRESP | Letter to the SEC | Oct 30, 2020 | — |
| CORRESP | Letter to the SEC | Oct 30, 2020 | — |
| CERT | Filing | Oct 29, 2020 | — |
| 8-A12B | Filing | Oct 29, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| S-1/A | Amended registration statement | Oct 16, 2020 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750149
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.